Anixa Biosciences Inc.
ANIX | NASDAQ
$2.71
+$0.01 (+0.37%)
Sep 22, 2026, 1:11 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Oct 30, 2025 | FY 2024 Oct 30, 2024 | FY 2023 Oct 30, 2023 | FY 2022 Oct 30, 2022 | FY 2021 Oct 30, 2021 | FY 2020 Oct 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 210K | n/a | 512K | n/a |
Cost of Revenue | 36K | n/a | 161K | n/a | 385K | 90.16K |
Gross Profit | -36K | n/a | 49K | n/a | 127K | -90.16K |
Operating Income | -11.7M | -13.83M | -11.01M | -13.88M | -13.14M | -9.98M |
Interest Income | 673K | 1.13M | 1.08M | 104K | 2.32K | 33.92K |
Pretax Income | -11.03M | -12.7M | -9.93M | -13.77M | -13.13M | -10.09M |
Net Income | -10.93M | -12.55M | -9.81M | -13.6M | -12.95M | -10.13M |
Selling & General & Admin | 6.63M | 7.44M | 6.29M | 7.17M | 7.07M | 5.51M |
Research & Development | 5.07M | 6.4M | 4.77M | 6.7M | 6.19M | 4.38M |
Other Expenses | -36K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 11.67M | 13.83M | 11.06M | 13.88M | 13.26M | 9.89M |
Interest Expense | n/a | n/a | n/a | 104K | 322 | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 11.7M | 13.83M | 11.22M | 13.88M | 13.65M | 9.98M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 32.45M | 31.9M | 30.98M | 30.37M | 28.58M | 22.23M |
Shares Outstanding (Diluted) | 32.45M | 31.9M | 30.98M | 30.37M | 28.58M | 22.23M |
EPS (Basic) | -0.34 | -0.39 | -0.32 | -0.45 | -0.45 | -0.46 |
EPS (Diluted) | -0.34 | -0.39 | -0.32 | -0.45 | -0.45 | -0.46 |
EBITDA | -10.99M | -12.66M | -9.88M | -13.73M | -13.08M | -10M |
EBIT | -11.03M | -12.7M | -9.93M | -13.77M | -13.14M | -10.09M |
Depreciation & Amortization | 36K | 37K | 46K | 42K | 59.86K | 90.16K |
Add to Watchlist
Select watchlists to add or remove ANIX